Robert S. Woodward
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert S. Woodward has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
L M Mundy
2 shared publicationsA. Kutinova
University of New Hampshire, Durham, New Hampshire, USA
1 shared publicationAndrea Kutinova
University of New Hampshire
1 shared publicationD L Lambert
1 shared publicationD. C. Brennan
Division of Nephrology, Washington University School of Medicine, St. Louis, MO
1 shared publicationD.C. Brennan
Washington University, St. Louis, Missouri, USA
1 shared publication
Latest Publications
- 14 July 2011
- Published by Wiley in Health Economics
- Vol. 21 (8) , 1023-1029
THE OH-SO STRAIGHT AND NARROW PATH: CAN THE HEALTH CARE EXPENDITURE CURVE BE BENT?
- 14 July 2011
- Published by Wiley in Health Economics
- Vol. 21 (8) , 1023-1029
THE OH-SO STRAIGHT AND NARROW PATH: CAN THE HEALTH CARE EXPENDITURE CURVE BE BENT?
- 1 June 2011
- Published by Elsevier in Value in Health
- Vol. 14 (4) , 443-449
The Long-Term Outcomes and Costs of Diabetes Mellitus among Renal Transplant Recipients: Tacrolimus versus Cyclosporine
- 1 June 2011
- Published by Elsevier in Value in Health
- Vol. 14 (4) , 443-449
The Long-Term Outcomes and Costs of Diabetes Mellitus among Renal Transplant Recipients: Tacrolimus versus Cyclosporine
- Open Access
- 11 November 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (12) , 2636-2646
Income-Related Disparities in Kidney Transplant Graft Failures Are Eliminated by Medicare’s Immunosuppression Coverage
- 11 November 2008
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (12) , 2636-2646
Open AccessIncome-Related Disparities in Kidney Transplant Graft Failures Are Eliminated by Medicare’s Immunosuppression Coverage
- Open Access
- 1 January 2006
- Published by Elsevier in American Journal of Transplantation
- Vol. 6 (1) , 129-139
The Incidence and Costs of Sepsis and Pneumonia Before and After Renal Transplantation in the United States
- 1 January 2006
- Published by Elsevier in American Journal of Transplantation
- Vol. 6 (1) , 129-139
Open AccessThe Incidence and Costs of Sepsis and Pneumonia Before and After Renal Transplantation in the United States
- Open Access
- 15 September 2005
- Published by Wolters Kluwer Health in Transplantation
- Vol. 80 (5) , 629-633
Renal Graft Survival and Calcineurin Inhibitor
Tacrolimus is associated with fewer acute rejections than cyclosporine, but a greater risk of new onset diabetes mellitus. When compared to no tacrolimus among nondiabetics in a large patient registry, it is associated with improved graft survival. The current study used the same patient registry to compare more correctly graft survival between nondiabetic renal transplant recipients initially immunosuppressed with either of the two most frequently used calcineurin inhibitors, tacrolimus or modified cyclosporine (CsA). We examined data provided by the United States Renal Data System (USRDS) on all first, single-organ, renal transplants to nondiabetic recipients that occurred during the years 1996 to 2000. Importantly, we then limited the study to patients on CsA (n=7,867) or tacrolimus (n=3,082) as the initial agent. Patients with both or neither were excluded. We used Cox proportional hazards regressions to estimate the tacrolimus-related relative risk of graft failure, controlling for other significant donor, recipient, and transplant characteristics We found that tacrolimus patients had graft failure rates equivalent to those of CsA patients (hazard ratio= 1.031, P=0.631) Although tacrolimus is being used with increasing frequency, analyses of the USRDS data show no net advantage in the ultimate transplantation outcome, graft survival. Given the higher acquisition price of tacrolimus compared to CsA and the similar risk of graft failure, further studies should be conducted to define those patient groups for which tacrolimus might be cost-effective.
- 15 September 2005
- Published by Wolters Kluwer Health in Transplantation
- Vol. 80 (5) , 629-633
Open AccessRenal Graft Survival and Calcineurin Inhibitor
Tacrolimus is associated with fewer acute rejections than cyclosporine, but a greater risk of new onset diabetes mellitus. When compared to no tacrolimus among nondiabetics in a large patient registry, it is associated with improved graft survival. The current study used the same patient registry to compare more correctly graft survival between nondiabetic renal transplant recipients initially immunosuppressed with either of the two most frequently used calcineurin inhibitors, tacrolimus or modified cyclosporine (CsA). We examined data provided by the United States Renal Data System (USRDS) on all first, single-organ, renal transplants to nondiabetic recipients that occurred during the years 1996 to 2000. Importantly, we then limited the study to patients on CsA (n=7,867) or tacrolimus (n=3,082) as the initial agent. Patients with both or neither were excluded. We used Cox proportional hazards regressions to estimate the tacrolimus-related relative risk of graft failure, controlling for other significant donor, recipient, and transplant characteristics We found that tacrolimus patients had graft failure rates equivalent to those of CsA patients (hazard ratio= 1.031, P=0.631) Although tacrolimus is being used with increasing frequency, analyses of the USRDS data show no net advantage in the ultimate transplantation outcome, graft survival. Given the higher acquisition price of tacrolimus compared to CsA and the similar risk of graft failure, further studies should be conducted to define those patient groups for which tacrolimus might be cost-effective.
- Top Cited PapersOpen Access
- 1 May 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (5) , 590-598
Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait-Listed and Transplanted Renal Allograft Recipients
This study sought to determine 1) the incidence and costs of new onset diabetes mellitus (NODM) associated with maintenance immunosuppression regimens following renal transplantation and 2) whether ...
- 1 May 2003
- Published by Elsevier in American Journal of Transplantation
- Vol. 3 (5) , 590-598
Top Cited PapersOpen AccessIncidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait-Listed and Transplanted Renal Allograft Recipients
This study sought to determine 1) the incidence and costs of new onset diabetes mellitus (NODM) associated with maintenance immunosuppression regimens following renal transplantation and 2) whether ...
- 8 December 1997
- Vol. 6 (1) , 17-22
Variations in healthcare measures by insurance status for patients receiving ventilator support.
To examine differences in healthcare delivery by expected health insurance status for hospitalized patients in diagnosis-related group (DRG) 475, respiratory system diagnoses requiring intubation and continuous ventilator support. A survey, derived from the Healthcare Cost and Utilization Project interstate database, of the care delivered to 21,149 adult patients in DRG 475 and hospitalized in one of 718 acute-care hospitals in nine states. Multivariate analysis was performed, controlling for demographic and hospital factors. Patients insured by health maintenance organizations (HMOs) had significantly lower rates of inpatient mortality (odds ratio [OR], 0.84; 95% confidence interval [CI95], 0.73-0.96), 14.3 more procedures performed (CI95, 11.5-17.2), 7.0% shorter hospitalizations (CI95, 12.5-1.6), and 5.2% higher charges (CI95, 0.4-10.0) than those with traditional private insurance. In addition, patients insured by Medicaid had 3.5% more procedures performed (CI95, 1.6-5.4), 10.4% longer lengths of hospitalization (CI95, 6.7-14.0), and 13.8% higher charges (CI95, 10.6-17.0) than those with traditional private insurance. Finally, the uninsured had significantly lower rates of inpatient mortality (OR, 0.87; CI95, 0.77-0.99), 8.5% more procedures performed (CI95, 6.0-11.1), 16.5% shorter hospitalizations (CI95, 21.5-11.6), and 13.4% lower charges (CI95, 17.8-9.0) than those with traditional private insurance. Variations in healthcare measures by insurance status for this DRG emphasize the importance of more careful analyses of insurance categories as a determinant of healthcare access and outcomes. Expected insurance status was an independent predictor of cost. Private insurance and HMO populations differed significantly in outcome and cannot be considered equivalent.
- 8 December 1997
- Vol. 6 (1) , 17-22
Variations in healthcare measures by insurance status for patients receiving ventilator support.
To examine differences in healthcare delivery by expected health insurance status for hospitalized patients in diagnosis-related group (DRG) 475, respiratory system diagnoses requiring intubation and continuous ventilator support. A survey, derived from the Healthcare Cost and Utilization Project interstate database, of the care delivered to 21,149 adult patients in DRG 475 and hospitalized in one of 718 acute-care hospitals in nine states. Multivariate analysis was performed, controlling for demographic and hospital factors. Patients insured by health maintenance organizations (HMOs) had significantly lower rates of inpatient mortality (odds ratio [OR], 0.84; 95% confidence interval [CI95], 0.73-0.96), 14.3 more procedures performed (CI95, 11.5-17.2), 7.0% shorter hospitalizations (CI95, 12.5-1.6), and 5.2% higher charges (CI95, 0.4-10.0) than those with traditional private insurance. In addition, patients insured by Medicaid had 3.5% more procedures performed (CI95, 1.6-5.4), 10.4% longer lengths of hospitalization (CI95, 6.7-14.0), and 13.8% higher charges (CI95, 10.6-17.0) than those with traditional private insurance. Finally, the uninsured had significantly lower rates of inpatient mortality (OR, 0.87; CI95, 0.77-0.99), 8.5% more procedures performed (CI95, 6.0-11.1), 16.5% shorter hospitalizations (CI95, 21.5-11.6), and 13.4% lower charges (CI95, 17.8-9.0) than those with traditional private insurance. Variations in healthcare measures by insurance status for this DRG emphasize the importance of more careful analyses of insurance categories as a determinant of healthcare access and outcomes. Expected insurance status was an independent predictor of cost. Private insurance and HMO populations differed significantly in outcome and cannot be considered equivalent.
- 1 March 1997
- Vol. 2 (2) , 82-7
Impact of risk adjustment estimators on ranking physician costs for pneumonia.
- 1 March 1997
- Vol. 2 (2) , 82-7
Impact of risk adjustment estimators on ranking physician costs for pneumonia.